Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 25;6:e2200085. doi: 10.1200/PO.22.00085

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 4. — Characteristics of HA cases and GS cases. (A) Per-patient HRR alteration type analysis in HA and/or GS cases, following stratification by sex and TP53 mutation status. Numbers in parentheses next to cancer types represent the number of cases in the four groups, respectively. (B) Comparisons of three gene expression–based HRD assessment scores after stratification by HA and GS. These scores were calculated from modification of the RPS, comparison between TCGA ovarian cancer samples, and KEGG pathway database, respectively (Data Supplement). *, **, and *** stand for P < .05, P < .01, and P < .001 in the Mann-Whitney U test, respectively. GS, genomic scar high; HA, HRR-altered; HRD, homologous recombination deficiency; HRR, homologous recombination repair; KEGG, Kyoto Encyclopedia of Genes and Genomes; OV-GS, TCGA ovarian cancer derived genomic scar score; RPS, recombination proficiency score; rRPS, reversed recombination proficiency score; TCGA, The Cancer Genome Atlas.